Baseline characteristics of the CASTING Study population: a Phase IIIB Trial evaluating Ocrelizumab in patients with relapsing-remitting Multiple Sclerosis and suboptimal response to disease-modifying therapies

被引：0
|
作者：
Vermersch, P. [1 ]
Comi, G. [2 ]
Siva, A. [3 ]
Oreja-Guevara, C. [4 ]
Wiendl, H. [5 ]
Van Wijmeersch, B. [6 ]
Eralinna, J. -P. [7 ]
Nicholas, R. [8 ]
Buffels, R. [9 ]
Bernasconi, C. [9 ]
Kuhelj, R. [9 ]
机构：
[1] Univ Lille, Lille, France
[2] Univ Vita Salute San Raffaele, Milan, Italy
[3] Istanbul Univ, Istanbul, Turkey
[4] Univ Hosp San Carlos, Madrid, Spain
[5] Univ Munster, Munster, Germany
[6] Univ Hasselt, Rehabil & MS Ctr Overpelt, BIOMED, Hasselt, Belgium
[7] Univ Turku, Turku, Finland
[8] Imperial Coll London, London, England
[9] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO2077
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [21] Efficacy/safety Of Ocrelizumab In Relapsing-remitting MS Patients With Suboptimal Response To Prior Disease-modifying Therapies (1-yr Interim Results)
    Vermersch, P.
    Eralinna, J.
    Nicholas, R.
    Oreja-Guevara, C.
    Siva, A.
    Van Wijmeersch, B.
    Wiendl, H.
    Buffels, R.
    Wei, W.
    Comi, G.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 32 - 32
  • [22] The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
    Biolato, Marco
    Bianco, Assunta
    Lucchini, Matteo
    Gasbarrini, Antonio
    Mirabella, Massimiliano
    Grieco, Antonio
    CNS DRUGS, 2021, 35 (08) : 861 - 880
  • [23] Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
    Lucchetta, Rosa C.
    Tonin, Fernanda S.
    Borba, Helena H. L.
    Leonart, Leticia P.
    Ferreira, Vinicius L.
    Bonetti, Aline F.
    Riveros, Bruno S.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    CNS DRUGS, 2018, 32 (09) : 813 - 826
  • [24] The prevalence and characteristics of epilepsy in patients with relapsing-remitting multiple sclerosis treated with disease-modifying therapy
    Kolcava, J.
    Kocica, J.
    Stourac, P.
    Bednarik, J.
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2020, 83 (04) : 424 - 427
  • [25] Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
    Diouf, Ibrahima
    Malpas, Charles B.
    Sharmin, Sifat
    Roos, Izanne
    Horakova, Dana
    Kubala Havrdova, Eva
    Patti, Francesco
    Shaygannejad, Vahid
    Ozakbas, Serkan
    Eichau, Sara
    Onofrj, Marco
    Lugaresi, Alessandra
    Alroughani, Raed
    Prat, Alexandre
    Duquette, Pierre
    Terzi, Murat
    Boz, Cavit
    Grand'Maison, Francois
    Sola, Patrizia
    Ferraro, Diana
    Grammond, Pierre
    Yamout, Bassem
    Altintas, Ayse
    Gerlach, Oliver
    Lechner-Scott, Jeannette
    Bergamaschi, Roberto
    Karabudak, Rana
    Iuliano, Gerardo
    McGuigan, Christopher
    Cartechini, Elisabetta
    Hughes, Stella
    Sa, Maria Jose
    Solaro, Claudio
    Kappos, Ludwig
    Hodgkinson, Suzanne
    Slee, Mark
    Granella, Franco
    de Gans, Koen
    McCombe, Pamela A.
    Ampapa, Radek
    van der Walt, Anneke
    Butzkueven, Helmut
    Sanchez-Menoyo, Jose Luis
    Vucic, Steve
    Laureys, Guy
    Sidhom, Youssef
    Gouider, Riadh
    Castillo-Trivino, Tamara
    Gray, Orla
    Aguera-Morales, Eduardo
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2023, 94 (12) : 1004 - 1011
  • [26] Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment
    Grand'Maison, Francois
    Yeung, Michael
    Morrow, Sarah A.
    Lee, Liesly
    Emond, Francois
    Ward, Brian J.
    Laneuville, Pierre
    Schecter, Robyn
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (08) : 1419 - 1430
  • [27] EFFICACY AND SAFETY OF DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS: A SYSTEMATIC REVIEW
    Lingohr-Smith, M.
    Deitelzweig, C.
    Lin, G.
    Lin, J.
    VALUE IN HEALTH, 2021, 24 : S158 - S158
  • [28] The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review
    Shahtaheri, Rahil Sadat
    Nikfar, Shekoufeh
    Khorasani, Elahe
    Sabbagh-Baniazad, Mansoureh
    Goudarzi, Zahra
    Emamikhah, Maziar
    CURRENT JOURNAL OF NEUROLOGY, 2020, 19 (03): : 138 - 145
  • [29] Disease-modifying therapy in relapsing-remitting multiple sclerosis: efficacy is paramount
    Cristiano, E
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, : 3 - 7
  • [30] Discontinuation of Disease-Modifying Therapy for Patient with Relapsing-Remitting Multiple Sclerosis
    Yano, Hajime
    Gonzalez, Cindy T.
    Healy, Brian C.
    Glanz, Bonnie I.
    Weiner, Howard L.
    Chitnis, Tanuja
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 47 - 47
12345